Você procurou por: cytarabine (Inglês - Dinamarquês )

cytarabine
cytarabin

depocyte cytarabine
depocyte cytarabin

• depocyte • cytarabine
depocyte cytarabine

· depocyte · cytarabine · part b
depocyte cytarabine part b

the active substance is cytarabine.
aktivt stof: cytarabin.

cytarabine is an analogue of pyrimidine.
cytarabin er en analog af pyrimidin.

each 5 ml vial contains 50 mg cytarabine
hvert 5 ml hætteglas indeholder 50 mg cytarabin.

4, 43) in the unencapsulated cytarabine arm.
4, 43) i den uindkapslede arm.

depocyte 50 mg suspension for injection cytarabine
depocyte 50 mg injektionsvæske suspension cytarabin

international non-proprietary name (inn): cytarabine
internationaler freiname (inn):cytarabin

each vial contains 50 mg cytarabine (10 mg/ml).
hvert hætteglas indeholder 50 mg cytarabin (10 mg/ml).

incorporation into dna and rna may also contribute to cytarabine cytotoxicity.
inkorporering i dna og rna kan også bidrage til cytarabins cytotoksicitet.

each 5 ml vial contains 50 mg cytarabine (10 mg/ ml).
hvert 5 ml- hætteglas indeholder 50 mg cytarabin (10 mg/ ml).

- the active substance is 50 mg cytarabine (10 mg/ ml)
- det aktive stof er 50 mg cytarabin (10 mg/ ml)

cytarabine has been used as an anti-cancer medicine since the 1970s.
cytarabin wird seit den 1970er jahren als krebsmedikament eingesetzt.

anaphylactic reactions following intravenous administration of free cytarabine have been rarely reported.
anafylaktiske reaktioner efter intravenøs indgift af frit cytarabin er kun sjældent rapporteret.

it is not known whether cytarabine is excreted in human milk following intrathecal administration.
det vides ikke, om cytarabin udskilles i modermælk efter intratekal indgift.

as a result, cytarabine inhibits growth of tumour cells and eventually kills them.
derved hæmmer cytarabin væksten af kræftceller, der til sidst dør.

in cml, more patients who received introna with cytarabine were still alive after 3 years than patients who only received introna.
blandt patienterne med kronisk myeloid leukæmi var flere i live efter 3 år i den gruppe, som fik introna sammen med cytarabin, end i gruppen behandlet med introna alene.

in cml, more patients who received introna with cytarabine were still alive after three years than patients who only received introna.
blandt patienterne med kronisk myeloid leukæmi var flere i live efter 3 år i den gruppe, som fik introna sammen med cytarabin, end i gruppen behandlet med introna alene.